Clinical Trial of Polyherbal Formulation COVI-RB01 As An Add-On Therapy With Standard of Care In Mild And Moderate Covid-19 Positive Patients

A Study To Assess Efficacy And Safety Of Polyherbal Formulation (COVI-RB01) As An Add-On Therapy With Standard of Care In Mild And Moderate Covid-19 Positive Patients - COVI-RB01

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037378

Enrollment

130

Registered

2021-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - RT-PCR based diagnosis of COVID-19 - Treatment trials: cases of mild and moderate severity. - Willingness to participate.

Exclusion criteria

Exclusion criteria: - Severe category (Spo2 - Individuals with uncontrolled, unstable co-morbidities. - Individuals with pre-existing respiratory conditions. Immuno-compromised individuals or those on immuno-suppressants. - Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
- Two Point recovery on 10-point WHO Ordinal Scale. - Time to Clinical ImprovementTimepoint: During regimen and upto 14 days	—

Secondary

Measure	Time frame
- Time taken to get COVID-19 RT-PCR test negative. - Adverse eventsTimepoint: Upto 14 days	—

Countries

India

Contacts

Public ContactSudarshan Behera

Dr D. Y. Patil College of Ayurveda Hospital and Research Centre

drprashantkhade@gmail.com

Outcome results